Abstract 1544: Cell penetrating single domain antibody (sdAb) SBT-100 binds KRAS and inhibits growth of human cancers with KRAS activating mutations

• Published in: Cancer research (Chicago, Ill.) Vol. 79; no. 13_Supplement; p. 1544
• Main Authors: Singh, Sunanda, Murillo, Genoveva, Singh, Avani, Singh, Samara, Parihar, Meenakshi, Singh, Anjali, Mehta, Rajendra, Parihar, Ashutosh
• Format: Journal Article
• Language: English
• Published: 01.07.2019

Abstract Background: Despite nearly fourth years of research, scientists have failed to develop a clinically viable therapy against KRAS, one of the deadliest families of cancer-causing proteins. Mutations in KRAS are prevalent amongst the top three most deadly cancer types in the United States: pan...